New Perspectives of Dyrk1A Role in Neurogenesis and Neuropathologic Features of Down Syndrome
- PMID: 24465139
- PMCID: PMC3897685
- DOI: 10.5607/en.2013.22.4.244
New Perspectives of Dyrk1A Role in Neurogenesis and Neuropathologic Features of Down Syndrome
Abstract
Down syndrome (DS) is one of the most common genetic disorders accompanying with mental retardation, cognitive impairment, and deficits in learning and memory. The brains with DS also display many neuropathological features including alteration in neurogenesis and synaptogenesis and early onset of Alzheimer's disease (AD)-like symptoms. Triplication of all or a part of human chromosome 21, especially the 21q22.1~21q22.3 region called 'Down syndrome critical region (DSCR)', has been considered as the main cause of DS. One gene product of DSCR, dual-specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A), has been highlighted as a key contributor to the neural consequences of DS. This minireview summarizes accumulating recent reports about Dyrk1A involvement in the neuritogenesis, synaptogenesis, and AD-like neurofibrillary tangle formation, which is mainly focusing on Dyrk1A-mediated regulation of cytoskeletal proteins, such as tubulin, actin, and microtubule-associated protein tau. Understanding the molecular mechanisms of these phenomena may provide us a rational for new preventive and therapeutic treatment of DS.
Keywords: Dyrk1A; cytoskeletal proteins; down syndrome; neuritogenesis; synaptogenesis.
Similar articles
-
Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of Down syndrome.Mol Cell Neurosci. 2007 Oct;36(2):270-9. doi: 10.1016/j.mcn.2007.07.007. Epub 2007 Jul 24. Mol Cell Neurosci. 2007. PMID: 17720532
-
A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.J Neurochem. 2015 May;133(3):440-51. doi: 10.1111/jnc.13018. Epub 2015 Jan 26. J Neurochem. 2015. PMID: 25556849
-
Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.Neurobiol Dis. 2017 Oct;106:76-88. doi: 10.1016/j.nbd.2017.06.010. Epub 2017 Jun 21. Neurobiol Dis. 2017. PMID: 28647555
-
Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1.BMB Rep. 2009 Jan 31;42(1):6-15. doi: 10.5483/bmbrep.2009.42.1.006. BMB Rep. 2009. PMID: 19192387 Review.
-
The role of DYRK1A in neurodegenerative diseases.FEBS J. 2011 Jan;278(2):236-45. doi: 10.1111/j.1742-4658.2010.07955.x. Epub 2010 Dec 13. FEBS J. 2011. PMID: 21156028 Free PMC article. Review.
Cited by
-
Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A.Eur J Hum Genet. 2015 Nov;23(11):1482-7. doi: 10.1038/ejhg.2015.29. Epub 2015 Apr 29. Eur J Hum Genet. 2015. PMID: 25920557 Free PMC article.
-
Insights from the protein interaction Universe of the multifunctional "Goldilocks" kinase DYRK1A.Front Cell Dev Biol. 2023 Oct 12;11:1277537. doi: 10.3389/fcell.2023.1277537. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37900285 Free PMC article. Review.
-
DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B.PLoS One. 2018 Nov 29;13(11):e0207779. doi: 10.1371/journal.pone.0207779. eCollection 2018. PLoS One. 2018. PMID: 30496304 Free PMC article.
-
Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.Mol Genet Genomic Med. 2017 Sep 20;5(5):451-465. doi: 10.1002/mgg3.334. eCollection 2017 Sep. Mol Genet Genomic Med. 2017. PMID: 28944229 Free PMC article. Review.
-
Protein phosphatase PPM1B inhibits DYRK1A kinase through dephosphorylation of pS258 and reduces toxic tau aggregation.J Biol Chem. 2021 Jan-Jun;296:100245. doi: 10.1074/jbc.RA120.015574. Epub 2021 Jan 8. J Biol Chem. 2021. PMID: 33380426 Free PMC article.
References
-
- Down JL. Observations on an ethnic classification of idiots. 1866. Ment Retard. 1995;33:54–56. - PubMed
-
- Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat Rev Genet. 2004;5:725–738. - PubMed
-
- Roizen NJ, Patterson D. Down's syndrome. Lancet. 2003;361:1281–1289. - PubMed
-
- Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000;355:165–169. - PubMed
-
- Lejeune J, Gautier M, Turpin R. Study of somatic chromosomes from 9 mongoloid children. C R Hebd Seances Acad Sci. 1959;248:1721–1722. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources